“Teething Problems” Seen with FMD Implementation: No Shortages but Much Confusion
This article was originally published in The Gold Sheet
Executive Summary
There are “teething problems” in the implementation of the active substance import provisions of FMD, said one EU industry representative while another official called things “a mess” as member states and industry work to sort things out - but the feared drug shortages have not materialized as major API producing countries have ramped up at the last minute and are producing the written declarations attesting that their APIs meet EU GMP requirements.
You may also be interested in...
Program Participants Urge The FDA To Adopt Some Pharmaceutical Quality Metrics And Avoid Others
Site-based metrics praised; lot acceptance rates, invalidated OOS rates discouraged. Agency official admits some proposed metrics were “not the best.”
EU GMP Annex I Is A Top Priority For EMA While Industry Has Lingering Concerns
Questions about contamination control strategy raised as European Medicines Agency makes EU GMP Annex I revision a top priority in its 2021 work plan.
US FDA Mulls Advance Notice On Domestic Surveillance Inspections Post-COVID
Criticized for giving foreign sites advance notice of inspections, agency is considering giving such notice to domestic sites too even after surprise inspections become possible.